Kairos Pharma (NYSE American: KAPA) has announced positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 in combination with apalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC). The analysis revealed a statistically significant improvement in progression-free survival (PFS), with a median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared to just 2 months for those receiving apalutamide alone (P=0.0008). This dramatic difference underscores the potential of ENV-105 to address a critical unmet need in prostate cancer treatment.
The implications of these results are substantial for both patients and the company. If validated in later trials, ENV-105 could become a key component of combination therapy for mCRPC, a setting where resistance to standard androgen deprivation therapies is common and outcomes remain poor. The 15.7-month improvement in median PFS suggests that adding ENV-105 may overcome resistance mechanisms, potentially extending the time before disease progression and offering patients more effective treatment options. For Kairos Pharma, these data could accelerate clinical development and attract partnership or investment interest, as the company seeks to advance ENV-105 through the pipeline.
In response to the interim findings, Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression. Specifically, patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor will now be randomized to receive either enzalutamide alone or enzalutamide in combination with ENV-105. This change is intended to expand the eligible patient population and facilitate enrollment, with completion of the Phase 2 trial targeted in or before the fourth quarter of 2027. By intervening earlier, the company hopes to demonstrate even greater benefit and potentially streamline the path to regulatory approval.
ENV-105 is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Kairos Pharma, based in Los Angeles, California, is utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's focus on CD105 as a therapeutic target is supported by its role in tumor angiogenesis and immune evasion, making it an attractive candidate for combination strategies.
For investors and industry observers, the interim data provide encouraging evidence of ENV-105's potential. The statistically significant PFS benefit, coupled with a manageable safety profile (as implied by the trial's continuation), positions Kairos Pharma as a notable player in the competitive oncology landscape. The protocol amendment to include earlier-stage patients may also broaden the addressable market and enhance the commercial viability of ENV-105 if approved. For more details, the full press release is available at https://ibn.fm/EDpxx. The latest news and updates relating to KAPA can be found in the company's newsroom at https://ibn.fm/KAPA.
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, disseminated this announcement. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, along with article and editorial syndication to 5,000+ outlets. The platform also offers press release enhancement to ensure maximum impact, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BioMedWire aims to serve private and public companies seeking to reach investors, influencers, consumers, journalists, and the general public. For more information, visit BioMedWire. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
